News & Events
22 Dec 2011 Invitation to apply to become an independent assessor of group 2 driving licence applicants
People with diabetes treated with insulin are now able to apply for any group two driving licence . The process of assessment will be
1) A driver wishing to apply for a Group 2 licence will first have to fill out a self-declaration form and consent.
2)Information will be obtained from their clinician (Consultant or GP). This will generate a fee that will be paid by the DVLA. Applicants who clearly fail on the criteria will not proceed further. Applicants whose application is rejected can reapply in the future if their circumstances change.
3) The DVLA will refer applicants who meet the criteria for an independent assessment by a consultant diabetologist, who will report to DVLA. A fee will be paid by the DVLA.
4) The final decision as to fitness to drive a class 2 vehicle will lie with the DVLA.
5) There is a right of appeal to a local magistrates or sheriffs court.
Although local diabetologists known to the patient may be involved at stage 2, the DVLA requires a rigorous independent assessment at stage 3. ABCD has agreed to assist the DVLA in identifying assessors for stage 3 (the independent assessment).Discussions are proceeding to set up a training programme for any consultant diabetologist holding a CST wishing to be an independent assessor. Meanwhile in view of the need to establish the assessment process without delay, consultants holding a CST in diabetes who feel that they have appropriate experience are invited to apply to the DVLA using the attached form.
Click here to download the application form.
Our data suggest that ageing is associated with a progressive decline in ß-cell mitochondrial function that negatively impacts on the fine tuning of Ca2+ dynamics. This is conceptually important since it emphasizes that even relatively modest changes in ß-cell signal-transduction over time lead to compromised insulin release and a diabetic phenotype (Diabetes)
Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies
The specificity and sensitivity of commercially available kits for analysis of GLP-1 levels varies considerably. This should be taken into account when selecting which assay to use and when comparing data from different studies (Diabetes, Obesity and Metabolism)
This study provided evidence of the generalized nature of diabetic autonomic neuropathy. Diabetes patients with signs and symptoms of upper GI dysfunction displayed reduced rectal sensitivity to heat and mechanical and electrical stimulation. Also, the heart rate variability was impaired. In a clinical setting, the presence of autonomic dysfunction could be regarded as a diffuse neuropathic complication (Journal of Diabetes Research)
The association between retinal vascular geometry changes and diabetic retinopathy and their role in prediction of progression – an exploratory study
The study findings suggest that RVG alterations can act as novel markers indicative of progression of DR severity and establishment of PDR. RVG may also have a potential predictive role in determining the risk of future retinopathy progression (BMC Ophthalmology)
The Effect of Diabetes Self-Management Education on Body Weight, Glycemic Control, and Other Metabolic Markers in Patients with Type 2 Diabetes Mellitus
DSME, even though in low intensity, significantly improved the glycemic and body weight control in patients with type 2 diabetes (Journal of Diabetes Research)